Merck, Inc.
Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT03188523
- Locations
- 🇩🇪
Charite Research Organisation GmbH. ( Site 0002), Berlin, Germany
🇬🇧St Stephen's Clinical Research ( Site 0001), London, United Kingdom
Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
- Conditions
- Clostridium Difficile Infection
- Interventions
- Biological: BezlotoxumabDrug: PlaceboDrug: Antibacterial drug treatment (ABD)
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 148
- Registration Number
- NCT03182907
- Locations
- 🇿🇦
Red Cross War Memorial Children's Hospital ( Site 2601), Cape Town, Western Cape, South Africa
🇦🇷Hospital Privado de Cordoba ( Site 2102), Cordoba, Argentina
🇨🇴Hospital Pablo Tobon Uribe-Infectology pediatric ( Site 2166), Medellin, Antioquia, Colombia
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 415
- Registration Number
- NCT03179436
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center ( Site 0013), Gilbert, Arizona, United States
🇦🇺Melanoma Institute Australia ( Site 0017), Wollstonecraft, New South Wales, Australia
🇨🇱Fundacion Arturo Lopez Perez ( Site 5601), Santiago, Region M. De Santiago, Chile
A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)
- Conditions
- Acute Bacterial Skin and Skin Structure Infections
- Interventions
- Drug: Comparator
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT03176134
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0129), Chicago, Illinois, United States
🇧🇷Inst de Medicina Integral Professor Fernando Figueira- IMIP ( Site 0277), Recife, Pernambuco, Brazil
🇧🇬UMHAT Deva Maria ( Site 0333), Burgas, Bulgaria
Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
- Conditions
- Type 2 Diabetes MellitusType 1 Diabetes Mellitus
- Interventions
- Drug: MK-1092, 4.0 nmol/kgDrug: MK-1092, 64 nmol/kgDrug: Glargine 3.0 nmol/kgDrug: MK-1092, 32 nmol/kgDrug: MK-1092, 8.0 nmol/kgDrug: MK-1092, 16 nmol/kgDrug: Placebo to glargineDrug: Placebo to MK-1092Drug: Lispro 1.2 nmol/kgOther: DextroseBiological: Insulin
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 69
- Registration Number
- NCT03170544
- Locations
- 🇺🇸
ProSciento Inc. ( Site 0001), Chula Vista, California, United States
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
- Conditions
- Vulvar CancerCervical CancerVaginal CancerGenital WartsHuman Papillomavirus Infection
- Interventions
- Biological: V503
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1212
- Registration Number
- NCT03158220
- Locations
- 🇧🇪
University of Antwerp ( Site 0004), Wilrijk, Belgium
🇪🇸CAP Centelles ( Site 0027), Centelles, Barcelona, Spain
🇧🇪Universitair Ziekenhuis Gasthuisberg ( Site 0005), Leuven, Belgium
Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT03143998
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
- Conditions
- Renal Cell Carcinoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 994
- Registration Number
- NCT03142334
- Locations
- 🇦🇺
Fiona Stanley Hospital ( Site 0702), Murdoch, Western Australia, Australia
🇺🇸Weinberg Cancer Institute at Franklin Square ( Site 0046), Baltimore, Maryland, United States
🇺🇸Beth Israel Deaconess Medical Ctr. ( Site 0044), Boston, Massachusetts, United States
Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)
- Conditions
- Hepatitis C Virus (HCV) Infection
- Interventions
- Drug: EBR/GZR (50 mg/100 mg) FDC
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 117
- Registration Number
- NCT03111108
- Locations
- 🇫🇷
CHU Amiens-Picardie - Hopital Sud ( Site 0217), Amiens, France
🇫🇷CHU Jean Minjoz ( Site 0213), Besancon, France
🇫🇷CHU Henri Mondor ( Site 0206), Creteil, France
The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03108924
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0001), Hialeah, Florida, United States
🇺🇸Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States